PB2258: PHASE 1 FIRST IN HUMAN STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND EFFICACY OF GRC54276, A NOVEL HPK1 THRONINE-KINASE INHIBITOR, IN ADVANCED SOLID TUMOURS AND LYMPHOMAS.

• Harsha Doddihal,
• Thomas Marron,
• Satheesh C T,
• Manuprasad Avaronnan,
• Rajnish Nagarkar,
• Vineet Govinda Gupta,
• Biju Benjamin,
• Nagaraj Gowda,
• Venkatesha Udupa,
• Nilanjana Biswas,
• Jatin Kadam,
• Priyanka Dhage,
• Adam Beltran,
• Nikhil Amin

Affiliations

Harsha Doddihal

1 Glenmark Pharmaceuticals, Clinical Sciences, Mumbai, India

Thomas Marron

2 The Tisch Cancer Institute, Hematology and Medical Oncology, New York, United States

Satheesh C T

3 HCG, Hematology and Medical Oncology, Bengaluru, India

Manuprasad Avaronnan

4 Malabar Cancer Hospital, Hematology and Medical Oncology, Moozhikkara, India

Rajnish Nagarkar

5 HCG Manavata Cancer Centre, Surgical Oncology, Nashik, India

Vineet Govinda Gupta

6 Artemis Hospitals, Hematology and Medical Oncology, Gurugram, India

Biju Benjamin

7 Glenmark Pharmaceuticals, Pharmacokinetics, Mumbai, India

Nagaraj Gowda

8 Glenmark Pharmaceuticals, Immuno Biology, Mumbai, India

Venkatesha Udupa

9 Glenmark Pharmaceuticals, Toxicology, Mumbai, India

Nilanjana Biswas

10 Glenmark Pharmaceuticals, DMPK, Mumbai, India

Jatin Kadam

11 Glenmark Pharmaceuticals, Clinical Development, Mumbai, India

Priyanka Dhage

12 Glenmark Pharmaceuticals, Biostatistics, Mumbai, India

Adam Beltran

13 Glenmark Pharmaceuticals, Clinical Sciences Oncology, New Jersey, United States

Nikhil Amin

13 Glenmark Pharmaceuticals, Clinical Sciences Oncology, New Jersey, United States